Sree Rayalaseema Hi-Strength Hypo Limited manufactures chemicals including sodium hypochlorite and related products used in water treatment, pharmaceuticals and industrial applications. Its business benefits from demand for industrial and water-treatment chemicals. Capacity expansion and product diversification provide opportunities. Raw-material and energy costs, industrial demand, environmental regulations, capacity utilization and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹880 cr | ₹698 cr | ₹92 cr | 9.5 | 54.09 | 0.91 | 9.5% | 10.2% | 12.7% | 0.00 | ₹38 cr | 3.6 | 1.16 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 211 | 25 | 14.53 | +11.3% | +17.0% | 11.7% |
| Mar 2026 | 163 | 20 | 11.83 | -7.6% | +1.7% | 12.3% |
| Dec 2025 | 141 | 24 | 14.16 | +12.7% | +1.9% | 16.8% |
| Sep 2025 | 182 | 23 | 13.57 | -7.9% | +7.1% | 12.8% |
| Jun 2025 | 180 | 22 | 13.06 | +20.4% | +6.9% | 12.4% |
| Mar 2025 | 160 | 22 | 12.81 | +12.5% | -2.8% | 13.7% |
| Dec 2024 | 138 | 22 | 12.56 | +29.6% | -35.4% | 15.6% |
| Sep 2024 | 170 | 25 | 14.74 | +36.9% | -24.5% | 14.9% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✗ Fail |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✗ Fail |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 384.00 ✓ Within 25% of the 52-week high · high 627.70 ✗ RS percentile 70 or more · RS 53 Trend template - the gate, measured: a modest 21-day edge. | 6/8 | 6 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✗ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 627.70 ✗ S more volume on up days than down days (50 sessions) · 1.00x ✗ L RS percentile 80 or more · RS 53 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 1/6 | Weak |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 670.00 ✓ Box bottom confirmed (3 sessions holding) · bottom 519.20 ✗ Close above the box top · close 512.55 ✗ Volume at least 1.5x its 50-day average · 0.5x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 30/100 | Broken |
| Turtle | ✗ Close above the prior 55-session high · 670.00 ✗ Close above the prior 20-session high · 670.00 ✓ Close below the prior 20-session low · 519.20 Donchian channel breakout - the Turtle traders' entry. | Breakdown | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 27.5% — Return on capital (ROCE) · 12.7% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 84/100 | Strong |
| Graham | ✓ Price at or below the Graham number · Graham number 827.94 ✓ P/E 15 or less · P/E 9.5 ✓ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 0.91 ✓ Current ratio 2 or more · 10.51 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 100/100 | Undervalued |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✗ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 10.51 ✓ No new shares issued ✗ Margin rising (net margin) ✓ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 6/9 | Average |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRHHYPOLTD this stock | -2.0 | +5.5 | +6.3 | -5.9 | -13.4 | +50.5 | 9.5 | 0.91 | 9.5 | 12.7 | — | 0.00 | 3.6 | 880 | 698 | 92 | 54.1 | 1.16 |
| NOVARTIND | -6.1 | +15.2 | +93.0 | +185.8 | +169.7 | +140.4 | 47.5 | 5.80 | 12.0 | — | — | — | — | 4,745 | — | — | 39.6 | — |
| PREMIERPOL | +30.2 | +43.3 | +103.1 | +140.8 | +275.1 | +641.0 | 30.1 | 6.69 | 24.1 | 32.9 | — | 0.00 | 24.3 | 1,123 | 396 | 37 | 3.5 | 0.61 |
| CALSOFT | -18.4 | +38.8 | +158.0 | +79.1 | +128.5 | -13.1 | 13.5 | 4.79 | 32.3 | 42.0 | — | 0.04 | — | — | 25 | 15 | 2.4 | 0.57 |
| VALIANTLAB | +14.2 | +119.9 | +111.8 | +70.1 | -27.6 | — | 47.7 | 2.46 | -1.2 | 0.8 | — | 0.14 | 88.7 | 764 | 306 | 16 | 3.0 | 0.81 |
| KENNAMET | -3.8 | +48.0 | +67.3 | +66.3 | +56.4 | +189.5 | 46.2 | 10.60 | 23.0 | — | — | — | — | 9,052 | — | — | 89.2 | — |
| AKSHARCHEM | +5.8 | +76.5 | +98.6 | +57.4 | +48.9 | -20.8 | 23.7 | 1.27 | -0.2 | 0.7 | — | 0.41 | 23.5 | 333 | 416 | 14 | 17.5 | 0.81 |
| CHEMBONDCH | -17.5 | -11.4 | +49.0 | +48.5 | — | — | 15.9 | 2.92 | 18.5 | — | — | 0.00 | 12.1 | 605 | 347 | 38 | 14.2 | 1.28 |
| IVP | -2.1 | +33.7 | +47.2 | +34.0 | +23.5 | +77.2 | 6.9 | 1.38 | 12.6 | 13.9 | — | 0.42 | 7.5 | 217 | 611 | 32 | 30.5 | 1.05 |
| MARALOVER | -2.2 | +5.6 | +29.1 | +29.1 | -15.4 | -28.2 | — | 2.17 | — | — | — | — | — | — | — | — | — | 1.03 |
| NAHARSPING | -7.2 | -11.0 | -1.6 | +25.4 | -11.3 | -47.6 | 11.4 | 0.60 | 1.5 | 3.2 | — | 0.65 | 11.0 | 901 | 3,365 | 76 | 21.9 | 1.22 |